Online inquiry

IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5373MR)

This product GTTS-WQ5373MR is a type of mRNA modified with 5-Methyl-CTP, which ecodes the monoclonal antibody that targets env gene. The antibody can be applied in AIDS research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Pseudomonas aeruginosa; Homo sapiens
RefSeq NP_579894.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 155971
UniProt ID P04578
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ5373MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ15044MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SRF-231
GTTS-WQ11956MR IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MLTA3698A
GTTS-WQ9025MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA IMC RON-8
GTTS-WQ15629MR IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA VAY-736
GTTS-WQ14328MR IVTScrip™ mRNA-Anti-EGFL7, RG7414(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA RG7414
GTTS-WQ11194MR IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MEDI0562
GTTS-WQ15846MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ6890MR IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA E-6011
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW